Trial intelligence / Profile preview

RO7795081 drug-drug interaction and pharmacokinetics study in type 2 diabetes and obesity

NL-OMON60743Phase 1Completed

Sponsor
Roche
Start
Nov 2024
Modality
Small Molecules
Countries
1
01

Overview

Phase 1 trial of RO7795081 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Nov 2024; status: completed.

02

Drugs

RO7795081
03

Conditions

type 2 diabetes mellitus (T2DM)obesity

Beyond the preview

Go deeper on NL-OMON60743.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON60743.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call